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HS-1-associated protein X-1 (HAX-1) is a multi-functional protein that has been implicated in the
regulation of apoptosis, cell motility and calcium homeostasis. In the present study, we set out to
assess the postulated functional resemblance of HAX-1 to the BCL-2 family of anti-apoptotic pro-
teins using non-transformed, cytokine-dependent murine bone marrow cells as a model system.
BCL-XL, but not HAX-1 protected against cytokine withdrawal-induced apoptosis while HAX-1 and
BCL-XL signiﬁcantly reduced thapsigargin-triggered (calcium-dependent) apoptosis. The data argue
in favor of cell type- and stimulus-speciﬁc roles of HAX-1 in regulation of cell survival.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
HS-1-associated protein X-1 (HAX-1) is a 35-kDa protein [1]
that is ubiquitously expressed and which has been implicated in
multiple cellular processes such as apoptosis, cell migration, and
calcium homeostasis [for a review, see 2]. In particular, HAX-1
has attracted considerable attention in recent years for its potential
role in the regulation of apoptosis. Indeed, HAX-1 was shown to
interact with several key molecules involved in apoptosis [2, and
see below]. Moreover, patients with loss of HAX-1 expression
due to homozygous HAX1 mutations [3] display accelerated mito-
chondria-dependent apoptosis of myeloid progenitor cells in the
bone marrow, and neutropenia [4]. Patients with speciﬁc HAX1
mutations also display CNS symptoms [5]. Mice that are deﬁcient
for HAX-1 expression show extensive apoptosis of neurons in the
striatum and the cerebellum as well as loss of lymphocytes with
age in spleen, bone marrow and thymus [6]. Interestingly, in
another study, the deletion of HAX-1 in mice resulted in a severe
reduction of lymphocytes in spleen, thymus and bone marrow,but the authors did not report any CNS abnormalities [7]. It is
noted that different mouse strains (C57Bl/6 vs. BALB/c) were
employed in the two studies [6,7].
HAX-1 is localized mainly in mitochondria, but also in the endo-
plasmic reticulum and nuclear envelope [1] and HAX-1 was shown
to be critical for maintaining the inner mitochondrial membrane
potential and protecting against apoptosis in myeloid cells [3].
The subcellular localization pattern of HAX-1 is reminiscent of
the expression pattern of BCL-2, a key regulator of mitochondria-
dependent apoptosis, and the presence of so-called BCL-2 homol-
ogy (BH) domains was suggested in early studies of HAX-1 [1].
However, more reﬁned bioinformatics analyses have called the
authenticity of that prediction into question [8]. Nonetheless, func-
tionally, HAX-1 shows similarities to the anti-apoptotic members
of the BCL-2 family acting at the level of mitochondria [3,9]. In
addition, HAX-1 also appears to resemble the inhibitor of apoptosis
(IAP) proteins, a family of endogenous caspase inhibitory proteins,
at least to some degree. Hence, overexpression of HAX-1 was
shown to inhibit caspase-9 in cardiomyocytes [10], and HAX-1
was recently shown to bind to X-linked IAP (XIAP) and to suppress
the polyubiquitination of XIAP [11], presumably leading to apopto-
sis inhibition by reducing the proteosomal degradation of XIAP, in
analogy with other IAP-IAP complexes [12]. Furthermore, HAX-1 is
cleaved in mitochondria by Omi/HTRA2 [13], a serine protease
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ﬁndings, the diversity of cell models and the frequent reliance on
overexpression approaches makes it difﬁcult to pinpoint the exact
mechanism of HAX-1 regulation of apoptosis. The cell type-speciﬁc
repertoire of HAX-1-binding partners may also come into play, and
the fact that multiple splice variants of HAX1 exist [5].
To further explore the role of HAX-1 in apoptosis we established
non-transformed, cytokine-dependent cell lines from murine bone
marrow obtained from wild-type or Hax1-deﬁcient mice [6]. We
speciﬁcally set out to examine the postulated functional resem-
blance of HAX-1 to anti-apoptotic BCL-2 family proteins repre-
sented in this study by BCL-XL. We hypothesized that the lack of
Hax-1 expression would increase the sensitivity to apoptosis
induced by cytokine withdrawal, and, moreover, that ectopic
expression of human HAX-1 and BCL-XL in Hax1-deﬁcient murine
cells would protect cells against withdrawal of cytokines. To com-
plement these studies, we also evaluated whether HAX-1 inﬂu-
enced BAX-induced apoptosis in HeLa cells with/without stable
silencing of HAX-1. Additionally, we assessed whether the expres-
sion of endogenous murine Hax-1 and/or expression of human
HAX-1 or BCL-XL would promote survival of bone marrow cells
upon deregulation of intracellular calcium.
2. Materials and methods
2.1. Cell lines
The human retroviral packaging cell line Phoenix-Eco (kindly
provided by Dr. G.P. Nolan, Stanford University, Stanford, CA)
was grown as described [15]. Bone marrow cells from wild-type
and Hax1 knock-out mice [6] kindly provided by Dr. J. N. Ihle (St.
Jude Children’s Research Hospital, Memphis, TN) were grown in
RPMI-1640 medium (Invitrogen) supplemented with 10% fetal calf
serum (FCS) (Invitrogen), 2 mM L-glutamine, 1 mM sodium pyru-
vate (Sigma–Aldrich), 10 mM HEPES (Sigma–Aldrich), 50 lM 2-
mercaptoethanol, 100 U/ml penicillin, 100 lg/ml streptomycin,
and interleukin (IL)-3 and stem cell factor (SCF) containing super-
natants [16]. Cells were subcultured by serial dilutions and adher-
ent cells were removed prior to further experiments. The Jurkat
leukemic T cell line was from the European Cell Culture Collection
(Salisbury, UK) and was maintained in RPMI-1640 medium supple-
mented with 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM
L-glutamine and 10% FCS. The HeLa human cervical carcinoma cell
line with stable HAX-1 silencing (miHAX1) and a corresponding
silencing control cell line (miNEG) were established using the
BLOCK-iT PolII miR RNAi expression vector system (Invitrogen)
as described previously [17] and cell lines were maintained in
DMEM medium (Invitrogen) supplemented with 100 U/ml penicil-
lin, 100 lg/ml streptomycin, 7.5 lg/ml blasticidin and 10% FCS.
2.2. Expression vectors
Enhanced Green Fluorescent Protein (EGFP) was fused to the
bleomycin resistance gene (Sh ble), obtained from pTracer-SV40
(Invitrogen), providing resistance to zeocin, and subsequently
ligated into the pMSCV-IRES-EGFP resulting in pMSCV-IRES-EGFPZ.
The pMSCV-BCL-XL-IRES-EGFPZ vector was generated by subclon-
ing the EcoRI-XhoI fragment containing human BCL-XL from the
pLXIN-BCL-XL expression vector [18]. Human HAX1 variants were
obtained as previously described [5] and cloned into the
pcDNA3.1(+) vector (Invitrogen). Subsequently, HAX1 coding
sequences were ampliﬁed with variant-speciﬁc forward and
reverse primers containing EcoRI and SalI restriction sites, respec-
tively, and cloned into EcoRI and XhoI sites of the pMSCV-IRES-
EGFPZ vector. Primer sequences are available on request. HumanBAX (isoform alpha) coding sequence was obtained by a standard
PCR on pTYB1-BAX plasmid (a generous gift from Dr. L.D. Walen-
sky, Dana-Farber Cancer Institute, Boston, MA), cloned into
pGEM-T Easy vector (PROMEGA) and subcloned into HindIII and
EcoRV sites of pcDNA3.1(+) mammalian expression vector (Invitro-
gen). Primer sequences are available on request.
2.3. Production of retroviral particles and retroviral transduction
Retroviral particles were produced as previously described [19]
with the exception that Phoenix-Eco packaging cells were transfec-
ted with 30 lg of the following plasmids: pMSCV-IRES-EGFPZ
(mock), pMSCV-BCL-XL-IRES-EGFPZ or pMSCV-HAX1-IRES-EGFPZ
(variants I–IV). Murine Hax1-deﬁcient cells were transduced by
two rounds of spin infection in the presence of 8 lg/ml polybrene
(Sigma–Aldrich). This was repeated for two consecutive days and
cells were then cultured without selection for another three days.
After two weeks of selection with 1 mg/ml zeocin (Invitrogen)
almost 100% of the cells were GFP-positive as measured by ﬂow
cytometry.
2.4. Western blot analysis
Western blot analysis was done as described previously [20].
Membranes were subsequently probed with antibodies against
HAX-1 (mouse monoclonal, BD Biosciences; rabbit polyclonal,
Santa Cruz Biotechnology), BCL-XL (rabbit polyclonal, Cell Signal-
ing), or BAX (rabbit polyclonal, Santa Cruz Biotechnology). After
stripping, membranes were re-probed with antibody against
beta-actin (mouse monoclonal, Sigma–Aldrich) or GAPDH (rabbit
polyclonal, Sigma–Aldrich) to ensure equal protein loading.
2.5. Flow cytometric determination of apoptosis
Apoptosis in pro-mast cell lines was induced by cytokine with-
drawal or by thapsigargin treatment. For cytokine deprivation,
cells were washed twice with PBS and resuspended in cell culture
medium without IL-3 and SCF. Cells were cytokine starved for 0, 3,
12, 24 or 48 h. For thapsigargin treatment, cells were incubated
with 0, 10, 25, 50, 75 or 100 nM of thapsigargin (Calbiochem) for
24 h. Apoptosis was determined by ﬂow cytometric quantiﬁcation
of phosphatidylserine (PS) exposure and DNA content. For detec-
tion of PS exposure cells were washed and resuspended in staining
solution containing Annexin V-PE and 7-AAD (Annexin V-PE detec-
tion kit I, BD Pharmingen). Hypodiploid DNA content was evalu-
ated as described previously following staining of permeabilized
cells with propidium iodide (PI) [20]. To measure the dissipation
of mitochondrial transmembrane potential (DWm) cells were incu-
bated for 15 min at 37 C in cell culture medium with 30 nM Mito-
Tracker Red CMXRos (Invitrogen), washed twice in PBS and
resuspended in PBS for further analysis. Cells were analyzed on a
FACSCalibur (BD Biosciences) operating with CellQuest software
(BD Biosciences). Apoptosis was induced in HeLa cells by transient
expression of human BAX from the pcDNA3.1(+)-BAX expression
vector; pcDNA3.1(+) was used for mock transfection. Transfections
were performed using Lipofectamine 2000 (Invitrogen), according
to the manufacturer’s instructions. The dissipation of mitochon-
drial transmembrane potential (DWm) was measured 24 h after
transfection as described above for the mast cell lines and cells
were analyzed on a FACSCalibur (BD Biosciences) operating with
CellQuest software (BD Biosciences).
2.6. Statistical analysis
The results are expressed as mean values ± S.D. The two-tailed
Mann–Whitney U test was used to compare overall responses to
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time-points or concentrations. The level of statistical signiﬁcance
was set at P < 0.05. The calculations were carried out with the data
analysis software system, STATISTICA, v. 10 (trial version),
www.statsoft.com.
3. Results
3.1. Hax-1 fails to protect bone marrow cells against cytokine
withdrawal-induced apoptosis
To establish a model for the assessment of the role of HAX-1
function in apoptosis we cultured primary cells derived from the
bone marrow of wild-type (WT) and Hax1-deﬁcient (Hax1 KO)
mice [6] in the presence of the cytokines/growth factors IL-3 and
SCF. Using these culture conditions, non-transformed cytokine-
dependent bone marrow-derived mast cells are obtained [21]. Dif-
ferential expression of endogenous mouse Hax-1 protein in
homogenous suspension cultures of WT and Hax1 KO cells was
conﬁrmed by Western blot (Fig. 1A). To compare the response of
WT and Hax1 KO cells to cytokine starvation, cells were cytokine
deprived for the indicated periods of time (Fig. 1B–D). Reduction
of mitochondrial transmembrane potential (Fig. 1B) was ﬁrst
detected 12 h after cytokine withdrawal and continued to drop
until 48 h, but we observed no differences in the kinetics of dissi-
pation of DWm between the two cell lines. The levels of apoptosis
were determined by monitoring PS exposure (Fig. 1C) and hypo-
diploid DNA content (Fig. 1D). Cytokine deprivation resulted in
apoptosis of almost all cells within 48 h for both cell lines. WT cells
showed slightly lower levels of PS exposure and hypodiploid DNAFig. 1. Hax-1 fails to protect bone marrow cells against cytokine withdrawal-induced a
(WT) and Hax1 knock-out (Hax1 KO) mice. Total cell lysates were probed with antibodie
from WT and Hax1 KO mice were cytokine deprived for 0, 3, 12, 24 or 48 h. The percenta
(C), and hypodiploid DNA content (D) were determined by ﬂow cytometry. Data are shocontent than Hax1 KO cells at 12 h, but the effect was not statisti-
cally signiﬁcant. These data indicate that endogenous Hax-1 does
not protect murine bone marrow-derived cells from cytokine
deprivation-induced apoptosis.
3.2. Human HAX-1 fails to protect Hax1-deﬁcient murine bone
marrow cells from apoptosis
To test if overexpression of human HAX-1 in Hax1 null murine
bone marrow cells can rescue cells from apoptosis induced by
cytokine deprivation, we performed retroviral transduction of
Hax1 KO cells using the pMSCV-IRES-EGFPZ vector encoding
human HAX-1 (isoform I). A stable cell line was established and
the successful selection was conﬁrmed by ﬂow cytometric detec-
tion of GFP ﬂuorescence (data not shown). Human BCL-XL and
mock (negative control) transfected cell lines were also generated.
Expression of HAX-1 and BCL-XL was conﬁrmed by Western blot
(Fig. 2A). Next, stable cell lines were cytokine starved to induce
apoptosis. Mitochondrial membrane potential (Fig. 2B) gradually
dropped in mock transfected cells but was maintained in cells
expressing human BCL-XL (overall response, mock vs. BCL-XL: P-
value 0.00004). Cells expressing human HAX-1, however, showed
a drop in DWm similar to the mock transfected cells (Fig. 2B). No
differences in DWm were seen in the three cell lines when cultured
in the presence of cytokines (data not shown). Furthermore, PS
exposure (Fig. 2C) and hypodiploid DNA content (Fig. 2D) measure-
ments showed no differences in the overall response to cytokine
withdrawal between mock and HAX-1 transfected cells. Slightly
lower levels of apoptosis were observed for the HAX-1 expressing
cells at 24 h (Fig. 2D), but the results were not statisticallypoptosis. (A) Western blotting of cells derived from the bone marrow of wild-type
s against HAX-1 and beta-actin (ACTB). (B–D) IL-3 and SCF-dependent cells derived
ges of cells with a drop in mitochondrial transmembrane potential (B), PS exposure
wn as mean values ± S.D. of three (B,C) or four (D) experiments.
Fig. 2. Human HAX-1 fails to protect Hax1-deﬁcient murine bone marrow cells from apoptosis. (A) Western blotting of murine Hax1 KO cells retrovirally transduced with
empty vector (mock) or vectors carrying human BCL-XL or HAX-1 (isoform I) coding sequences. Jurkat cells were included as a positive control for human HAX-1. Total cell
lysates were probed with antibodies against HAX-1, BCL-XL and ACTB. (B-D) Cell lines obtained by retroviral transduction as detailed in (A) were deprived of cytokines and the
percentages of cells with a drop in mitochondrial transmembrane potential (B), PS exposure (C), and hypodiploid DNA content (D) were determined by ﬂow cytometry. Data
are displayed as mean values ± S.D. of three (B,C) or four (D) experiments.
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tected against cytokine withdrawal-induced apoptosis, as deter-
mined by measurement of PS exposure (Fig. 2C) (overall
response, mock vs. BCL-XL: P-value 0.0003) and hypodiploid DNA
content (Fig. 2D) (overall response, mock vs. BCL-XL: P-value
0.00007).
We previously reported that human HAX-1 is alternatively
spliced [5]. Notably, alternative transcripts contain open reading
frames encoding putative HAX-1 isoforms. The potential roles of
these isoforms in apoptosis have not been evaluated previously.
To compare the effect of HAX-1 isoform expression on cytokine
withdrawal induced apoptosis, we retrovirally transduced Hax1
KO cells with pMSCV-IRES-EGFPZ vectors carrying HAX-1 isoforms
II–IV coding sequences. As shown in Fig. 3A, we conﬁrmed the
presence of HAX-1 isoforms II and III proteins, although the latter
was expressed at a very low level. Isoform IV of HAX-1 could not
be detected, using monoclonal or polyclonal HAX-1 antibody (data
not shown), and this cell line was therefore excluded from further
experiments. Using cell lines expressing HAX-1 isoform II (Fig. 3B)
or isoform III (Fig. 3C), the effect of cytokine deprivation on apop-
tosis was determined based on the percentage of cells displaying
hypodiploid DNA content. At the 24 h time-point the level of apop-
tosis for cells expressing HAX-1 isoform II was lower than for mock
transfected cells (Fig. 3B), but the effect was not statistically signif-
icant. At the 48 h time-point, the percentages of apoptosis in cells
expressing isoforms II and III were indistinguishable from mock
transfected cells. Thus, while enforced expression of HAX-1 may
delay apoptosis of murine bone marrow cells, HAX-1 does not
ultimately rescue these cells from apoptosis.3.3. Effect of HAX-1 silencing on BAX-induced apoptosis in the human
HeLa cell line
To further assess the role of HAX-1 in apoptosis, we determined
whether HAX-1 inﬂuences BAX-induced apoptosis in the human
HeLa cervical carcinoma cell line. To this end, we used HeLa cells
with stably silenced HAX-1 (miHAX1) and a corresponding silenc-
ing control cell line (miNEG). HAX-1 silencing (Suppl. Fig. 1A) and
BAX overexpression (Suppl. Fig. 1B) was conﬁrmed by Western
blot. Apoptosis was induced by transient transfection with a
human BAX-encoding expression vector vs. empty vector as a con-
trol and assessed by a drop in DWm 24 h after transfection (Suppl.
Fig. 1C) or by Western blotting for PARP cleavage, for caspase acti-
vation (data not shown). BAX overexpression induced signiﬁcant
apoptosis (P-value: 0.021) in miHAX1 and miNEG cell lines, but
no signiﬁcant differences were seen between the two cell lines,
showing that HAX-1 does not counteract BAX-induced apoptosis
in this model.
3.4. Effect of murine Hax-1 and human HAX-1 vs. BCL-XL on
thapsigargin-induced apoptosis
HAX-1 has been implicated in the regulation of cellular Ca2+
homeostasis and recent studies have shown that HAX-1 interacts
with the sarco(endo)plasmic reticulum (SR) Ca2+ transport ATPase
(SERCA2) and its inhibitor phospholamban (PLN) [22,23]. Ca2+
overload, or perturbation of intracellular Ca2+ compartmentaliza-
tion, in turn, is known to cause cytotoxicity and to trigger either
apoptotic or necrotic cell death [for a review, see 24]. To evaluate
Fig. 3. Expression of human HAX-1 variants in murine Hax1-deﬁcient cells. (A) Western blotting of murine Hax1 KO cells retrovirally transduced with vectors carrying human
HAX-1 isoform I, II or III coding sequences. Total cell lysates were probed with antibodies against HAX-1 and ACTB. Note that the membrane is overexposed with respect to
HAX-1 isoform II in order to enable the simultaneous visualization of HAX-1 isoform III on the same membrane. (B and C) Murine cell lines expressing HAX-1 isoform II (B) or
isoform III (C) were subjected to cytokine withdrawal for the indicated time-points and the percentages of cells with hypodiploid DNA content were determined by ﬂow
cytometry. Data are displayed as mean values ± S.D. of four (isoform III) or two (isoform II) experiments. Cells transduced with isoform IV were omitted from further analysis
as the expression of this variant was undetectable (data not shown).
Fig. 4. Effect of murine Hax-1 and human HAX-1 vs. BCL-XL on thapsigargin-induced apoptosis. Cells derived from the bone marrow of WT and Hax1 KO mice (A) or Hax1 KO
cells retrovirally transduced with an empty vector (mock) or vectors with human BCL-XL or HAX-1 (isoform I) coding sequences (B) were treated with 0, 10, 25, 50, 75 or
100 nM thapsigargin for 24 h. Apoptosis was determined by ﬂow cytometric detection of PS exposure. Data are shown as mean values ± S.D. of four independent experiments.
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Ca2+ imbalance, we treated murine bone marrow cell lines with
thapsigargin (TG). TG selectively inhibits SERCA2 which leads to
a passive release of Ca2+ from ER stores and a subsequent increase
in the cytosolic Ca2+ concentration, leading to apoptosis induction.
Increasing concentrations of TG induced apoptosis in both WT and
Hax1 KO cell lines (Fig. 4A). Notably, the levels of PS exposure were
signiﬁcantly lower in the WT cells (overall response, WT vs. Hax1
KO: P-value 0.0009), indicating a protective role of Hax-1 in this
model. Subsequent analysis of TG-treated Hax1 KO cells trans-
duced with human HAX-1 (isoform I) revealed lower levels ofapoptosis when compared to mock transfected cells, but the effect
was not statistically signiﬁcant (Fig. 4B). For comparison, cells
expressing BCL-XL were signiﬁcantly protected against TG-induced
apoptosis in comparison with the mock transfected cells (Fig. 4B;
overall response, mock vs. BCL-XL: P-value 0.00003).
4. Discussion
Using non-transformed, cytokine-dependent bone marrow cells
as a model system, we show herein that HAX-1 does not univer-
sally protect against apoptosis and, moreover, that HAX-1 does
2926 A. Trebinska et al. / FEBS Letters 588 (2014) 2921–2927not seem to act as a functional homolog of BCL-XL. We and others
have previously shown that HAX-1 protects myeloid progenitor
cells from apoptosis [3,4] and other authors have suggested that
Hax-1 may have a general function in protecting hematopoietic
cells from cytokine withdrawal [6]. However, contrary to our
expectations, neither the presence of endogenous murine Hax-1
nor the enforced expression of human HAX-1 in Hax1-deﬁcient
murine bone marrow cells provided protection from apoptosis or
the dissipation of DWm induced by cytokine/growth factor with-
drawal. On the other hand, overexpression of BCL-XL completely
rescued cells from apoptosis induced by cytokine withdrawal.
The latter ﬁnding is not unexpected given that BIM [21], a BH3-
only protein belonging to the BCL-2 family, and BAX [25], another
pro-apoptotic member of the BCL-2 family, were shown to regulate
cytokine deprivation-induced apoptosis in murine pro-mast cells.
It is worth mentioning that at early time points (12 and/or 24 h)
the expression of murine Hax-1 or human HAX-1 correlated with
a slightly reduced percentage of cells with hypodiploid DNA con-
tent, at least as far as isoforms I and II of HAX-1 are concerned;
the effect of isoform III should be interpreted with some caution
due to the low level of expression in murine cells, and the potential
effect of isoform IV could not be evaluated as its expression was
undetectable. However, this ‘‘preventive’’ effect was not seen at
later time-points (48 h of cytokine deprivation). Thus, while
HAX-1 may extend the window of survival upon cytokine starva-
tion, this does not ultimately rescue cells from apoptosis. Similarly,
we previously observed that HAX-1 expression delays, but does not
completely block apoptosis of human B cell lines incubated with
the serine protease inhibitor, TPCK [20]. In a very recent study pub-
lished during the preparation of this manuscript, the suggestion
was put forward that HAX-1 comprises a family of pro- and anti-
apoptotic proteins that may regulate cell survival through the for-
mation of homo- or heterodimers, much like members of the BCL-2
family [26]. Speciﬁcally, evidence was provided that different HAX-
1 variants have opposing roles in regulating apoptosis in a model of
H2O2-treated HEK293 epithelial cells. Notably, however, overex-
pression of HAX-1 in these cells had no effect on apoptosis induced
by thapsigargin or the Ca2+ ionophore calcimycin (also known as
A23187), nor on serum starvation-induced apoptosis, further sug-
gesting that cell type-speciﬁc differences exist in terms of the
apoptosis-regulatory actions of HAX-1 and its variants.
Chao et al. [6] reported that the rate of accumulation of acti-
vated BAX in peripheral T cells subjected to IL-2 withdrawal was
accelerated in cells from Hax1-deﬁcient animals. The authors pro-
posed that Hax-1 facilitates processing of the protease Omi/HTRA2
in mitochondria by another protease (PARL), and that this is
required to prevent BAX accumulation. However, other investiga-
tors have challenged this notion and found that endogenous
HAX-1 is neither resident within mitochondria or anchored to
the membranes of these organelles, and the suggestion that HAX-
1 resembles BCL-2 family proteins was discarded on the basis of
the absence of BH domains [8]. Our present observation that
HAX-1 deﬁciency does not inﬂuence cytokine deprivation-induced
apoptosis in primary murine bone marrow-derived mast cells, a
model of apoptosis previously shown to be BAX-dependent [25],
coupled with the demonstration that HAX-1 silencing fails to coun-
teract BAX-induced apoptosis in cervical carcinoma cells, further
implies that HAX-1 does not act like a BCL-2 family protein.
HAX-1 has been shown to regulate Ca2+ homeostasis by inter-
acting with endoplasmic reticulum proteins PLN and SERCA2
[22,23]. Indeed, HAX-1 was reported to play a role in Ca2+ cycling
in cardiomyocytes and to act as a regulator of cardiac function
[27]. In the present study, we found that the expression of endog-
enous Hax-1 afforded protection against thapsigargin-induced
apoptosis of murine, cytokine-dependent mast cell lines. Expres-
sion of human HAX-1 (isoform I) in Hax1-deﬁcient cells partiallyrecapitulated this effect, while the expression of human BCL-XL
in Hax1-deﬁcient murine cells provided signiﬁcant protection from
thapsigargin-induced apoptosis. Thus, Hax-1 protects against
apoptosis mediated by the SERCA2 inhibitor, thapsigargin, but does
not ultimately rescue cells from cytokine deprivation suggesting
that the effects are stimulus-speciﬁc. Moreover, it is pertinent to
note that HAX-1 has been ascribed several other roles, apart from
being a modulator of apoptosis, including in cell motility/migration
of neutrophils as well as of malignant cells [28,29] as well as mRNA
handling and/or processing [17,30] and as a putative regulator of
endolysosomal ion channels [31]. These mechanisms need not be
mutually exclusive but are likely cell-type dependent, as HAX-1
localization is in part dictated by the relative abundance of its
binding partners [2]. Interestingly, recent bioinformatics studies
have suggested that HAX-1 might bind Ca2+ directly [32]. This
remains to be proven experimentally, but if this were the case,
then HAX-1 could be an as yet uncharacterized intracellular Ca2+
‘‘sensor’’, whose inﬂuence on cellular Ca2+ stores indirectly regu-
lates cellular sensitivity to apoptosis. Further studies are war-
ranted to assess this possibility, and to determine whether this
putative, novel aspect of HAX-1 is universal or cell type-speciﬁc.
In addition, endolysosomal ion channels – to which HAX-1 may
bind – have been implicated as regulators of Ca2+ release [31,33].
In sum, the present ﬁndings obtained using non-transformed,
cytokine-dependent bone marrow cells along with other previous
studies in the literature suggest that the anti-apoptotic function
of HAX-1 (and its isoforms) is cell type- and/or stimulus-speciﬁc.
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